Perrigo to sell infant formula unit for up to $175M
Closing is expected in the first half of 2027, subject to customary closing conditions and regulatory approvals.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Perrigo Company plc (PRGO) entered a definitive agreement for MeridianMade to acquire its Infant Formula business for total consideration of up to $175 million: $40 million in cash at closing and up to $135 million contingent on future performance milestones through 2030.
Closing is expected in the first half of 2027, subject to customary closing conditions and regulatory approvals. Until closing, Perrigo will continue to own and operate the business, while it and MeridianMade operate independently. Infant Formula will remain in All In results for the third quarter of 2026 and, beginning in the fourth quarter, will be included in discontinued operations. In the trailing four quarters ended June 27, 2026, the business generated net sales of $380 million and segment adjusted operating income of $8 million. Perrigo expects a non-cash impairment charge of $275 million to $375 million in the fourth quarter of 2026. It also expects the transaction to enhance its margin profile, materially reduce expected future capital expenditures and make reported results more closely reflect Core Perrigo.
0 points · 0 major1 major · 1 point
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- None.
Negative
- Major point. Forward-looking: it has not happened yet and may not happen.Expected fourth-quarter 2026 non-cash impairment charge: $275 million to $375 million. 12% of market cap
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Total consideration: Up to $175 million
Cash at closing: $40 million
Contingent consideration: Up to $135 million
+3 more
6 metrics
Total consideration
Up to $175 million
Agreement for the Infant Formula business
Cash at closing
$40 million
Consideration under the agreement
Contingent consideration
Up to $135 million
Future performance milestones through 2030
Net sales
$380 million
Trailing four quarters ended June 27, 2026
Segment adjusted operating income
$8 million
Trailing four quarters ended June 27, 2026
Expected non-cash impairment charge
$275 million to $375 million
Expected in the fourth quarter of 2026
Key Terms
segment adjusted operating income, discontinued operations, non-cash impairment charge, Core Perrigo
4 terms
segment adjusted operating income financial
"segment adjusted operating income of $8 million"
Segment adjusted operating income is the profit a specific part of a business generates from its core activities after removing one-time items, unusual charges, or accounting quirks that can distort results. Investors use it to see how a particular division is really performing, like checking a player’s game stats after ignoring fluke plays, so they can compare divisions and track true operating trends over time.
discontinued operations financial
"included in discontinued operations"
Discontinued operations are parts of a company that it has decided to sell or shut down, and no longer plans to run in the future. This matters to investors because it helps them understand which parts of the business are ongoing and which are being phased out, providing a clearer picture of the company’s current performance and future prospects. Think of it like a store closing a department—it no longer contributes to sales or profits.
non-cash impairment charge financial
"record a non-cash impairment charge"
A non-cash impairment charge is an accounting write-down that lowers the recorded value of an asset on a company’s books when that asset is judged to be worth less than before. It reduces reported profit for the period without using any cash — like lowering the listed price of a used car in your records — and matters to investors because it can shrink earnings, change valuation metrics, and signal potential problems that might affect future cash flow or credit terms.
Core Perrigo financial
"financial profile of Core Perrigo"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much is Perrigo selling its Infant Formula business for?
The agreement provides for total consideration of up to $175 million, consisting of $40 million in cash at closing and up to $135 million contingent on future performance milestones through 2030.
What were Perrigo's Infant Formula sales and operating income?
In the trailing four quarters ended June 27, 2026, Infant Formula generated $380 million in net sales and $8 million in segment adjusted operating income.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_______________________________________________
FORM 8-K
______________________________________________
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
______________________________________________
(Exact name of registrant as specified in its charter)
_______________________________________________
Commission file number 001-36353
| Not Applicable | ||||||||
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||||
+353 1 7094000
(Address, including zip code, and telephone number, including
area code, of registrant’s principal executive offices)
Not Applicable
(Former name or former address, if changed since last report)
________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
(17 CFR 230.425)
(17 CFR 240.14a-12)
(17 CFR 240.14d-2(b))
(17 CFR 240.13e-4(c))
Securities Registered pursuant to section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 7.01 Regulation FD Disclosure
On October 29, 2026, Perrigo issued a press release announcing its entry into a definitive agreement to sell its Infant Formula business, a copy of which is attached hereto as Exhibit 99.1. Perrigo undertakes no obligation to update, supplement or amend the press release attached hereto as Exhibit 99.1.
The information in Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
ITEM 9.01. Financial Statements and Exhibits
(d)Exhibits
| Exhibit Number | Description | |||||||
| 99.1 | Press Release issued by Perrigo Company plc on October 29, 2026 furnished solely pursuant to Item 7.01 of Form 8-K. | |||||||
| 104 | Cover Page Interactive Data file (embedded within the Inline XBRL document). | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| (Registrant) | ||||||||||||||
| PERRIGO COMPANY PLC | ||||||||||||||
| By: | /s/ Eduardo Bezerra | |||||||||||||
| Dated: | October 29, 2026 | Eduardo Bezerra | ||||||||||||
| Chief Financial Officer | ||||||||||||||
Perrigo Announces Agreement to Divest Infant Formula Business to MeridianMade Advances Streamline pillar of Perrigo’s Three-S plan through portfolio simplification Furthers Perrigo’s evolution into a simpler, more focused consumer self-care company Expected to enhance Perrigo’s margin profile and eliminate significant expected future capital expenditures Aligns reported results more closely with the financial profile of Core Perrigo MeridianMade’s infant-grade, American manufacturing infrastructure and operating capabilities will support the continued supply of safe, high-quality, and affordable infant nutrition Dublin, Ireland – Perrigo Company plc (NYSE: PRGO) (“Perrigo” or “the Company”), a leading provider of consumer self-care products, today announced that it has entered into a definitive agreement pursuant to which MeridianMade, an American contract manufacturing platform dedicated to infant nutrition, will acquire Perrigo’s Infant Formula business for total consideration of up to $175 million. The transaction consists of $40 million in cash at closing and up to an additional $135 million contingent on the achievement of future performance milestones through 2030. This divestiture advances Perrigo’s evolution into a more focused consumer self-care company with a diversified portfolio of OTC products addressing essential, everyday health needs. The agreement follows a comprehensive review of strategic alternatives for the Infant Formula business and reflects careful consideration of the best path forward for the business and its stakeholders. MeridianMade is a company built entirely around infant nutrition with a singular focus on providing safe, high-quality formula to families and caregivers, with the infant-grade, domestic infrastructure and operating capabilities to support that aim. “Today’s announcement marks an important milestone in advancing the Streamline pillar of our Three-S plan to Stabilize, Streamline, and Strengthen the business,” said Albert Manzone, Interim President and Chief Executive Officer. “For Perrigo, this transaction is expected to enhance our margin profile, materially reduce expected future capital expenditures, and enable us to concentrate resources on strengthening our core consumer self-care portfolio. Our Infant Formula colleagues have worked with tremendous dedication to enhance performance and improve operations, which has positioned Infant Formula well for its next chapter. We are confident that with its singular focus on infant nutrition and commitment to quality, safety, and continuity, MeridianMade is the right manufacturer to carry this important category forward.” Ron Belldegrun, CEO of MeridianMade, and Mia Funt, President of MeridianMade, said, “This acquisition is a commitment to responsible stewardship of store-brand infant formulas, which offer American families a more affordable option for safe, high-quality infant nutrition. We look forward to working with the Perrigo team throughout the transition and continuing to support this critical source of infant nutrition.” Until closing, Perrigo’s Infant Formula business and MeridianMade will continue to operate as independent companies, and Perrigo will continue to own and operate the Infant Formula business with the same focus on safety, quality, reliable supply, and customer service. Closing is expected in the first half of 2027. The transaction is subject to the satisfaction of customary closing conditions and regulatory approvals. As a result of the transaction, Perrigo’s future reported results are expected to more closely reflect the financial profile of Core Perrigo, which Perrigo management believes will provide a clearer view of its ongoing business. Core Perrigo excludes Infant Formula and certain previously announced divestitures and exited products. Infant Formula will continue to be reported in All In results for the third quarter of 2026. Beginning in the fourth quarter of 2026, Infant Formula will be included in discontinued operations. In connection with the announced transaction, the Company expects to record a non-cash impairment charge in the fourth quarter of 2026 in the range of $275 to $375 million. In the trailing four quarters ended June 27, 2026, Infant Formula generated net sales of $380 million and segment adjusted operating income of $8 million. The transaction is expected to significantly reduce Perrigo’s future capital expenditure requirements.
Net proceeds from the transaction are expected to be used in accordance with Perrigo’s capital allocation priorities. Goldman Sachs is serving as financial advisor and A&O Shearman is serving as legal advisor for Perrigo. Jefferies LLC is serving as financial advisor and Sullivan and Cromwell LLP is serving as legal advisor to MeridianMade. About Perrigo Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the- counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. For more information, visit www.perrigo.com. About MeridianMade MeridianMade is a domestic, infant-focused nutrition platform dedicated to the development and manufacturing of high-quality infant formula. MeridianMade’s contract manufacturing services include spray drying, dry blending and packaging capabilities, supported by in-house R&D, clinical research, regulatory navigation and commercialization. For more information, visit https://meridianmade.us/. Forward-Looking Statements Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about the proposed divestiture of the Company’s Infant Formula business, including the timing and benefits thereof and the anticipated use of proceeds, our expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "forecast," "predict," "potential" or the negative of those terms or other comparable terminology. We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control, including our ability to complete the proposed divestment of the Infant Formula business, receipt of third-party approvals regarding the transaction, performance by counterparties to the transaction and the likelihood of satisfying the deferred payment milestones associated with the transaction, among others. These and other important factors, including those discussed in our Form 10-K for the year ended December 31, 2025 and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Perrigo Contacts Eric Jacobson, Vice President, Global Investor Relations (616) 886-0375, eric.jacobson@perrigo.com Nick Gallagher, Associate Director, Global Investor Relations (269) 686-3238, nicholas.gallagher@perrigo.com MeridianMade Contact press@meridianmade.us